We also found the gene expressions of multiple promising immunotherapy targets, including CD47, CD276, CTLA-4, LAG3, PD-1/L1, and TIM3, and tumor mutation burden (TMB) were significantly increased in the high-risk group, while the expression levels of NKG2A was significantly upregulated in the low-risk group than in the high-risk group (Figure 9B). The gene discussed is LAG3; the disease is neoplasm.